Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC.
Journal: JTO clinical and research reports
Published: March 05, 2025
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
Journal: Cancer chemotherapy and pharmacology
Published: August 21, 2017
Showing 1-2 of 2
Last Updated: 09/26/2026